Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE. Seiwert TY, et al. Among authors: kochanny s. Ann Oncol. 2019 Oct 1;30(10):1673. doi: 10.1093/annonc/mdz171. Ann Oncol. 2019. PMID: 31168601 Free article. No abstract available.
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Seiwert TY, Foster CC, Blair EA, Karrison TG, Agrawal N, Melotek JM, Portugal L, Brisson RJ, Dekker A, Kochanny S, Gooi Z, Lingen MW, Villaflor VM, Ginat DT, Haraf DJ, Vokes EE. Seiwert TY, et al. Among authors: kochanny s. Ann Oncol. 2019 Feb 1;30(2):297-302. doi: 10.1093/annonc/mdy522. Ann Oncol. 2019. PMID: 30481287 Free article. Clinical Trial.
Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience.
Rosenberg AJ, Agrawal N, Pearson A, Gooi Z, Blair E, Cursio J, Juloori A, Ginat D, Howard A, Chin J, Kochanny S, Foster C, Cipriani N, Lingen M, Izumchenko E, Seiwert TY, Haraf D, Vokes EE. Rosenberg AJ, et al. Among authors: kochanny s. Oral Oncol. 2021 Nov;122:105566. doi: 10.1016/j.oraloncology.2021.105566. Epub 2021 Oct 18. Oral Oncol. 2021. PMID: 34662771 Free PMC article. Clinical Trial.
A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
Seiwert TY, Kochanny S, Wood K, Worden FP, Adkins D, Wade JL, Sleckman BG, Anderson D, Brisson RJ, Karrison T, Stadler WM, Vokes EE. Seiwert TY, et al. Among authors: kochanny s. Cancer. 2020 Jul 15;126(14):3237-3243. doi: 10.1002/cncr.32929. Epub 2020 May 4. Cancer. 2020. PMID: 32365226 Free article. Clinical Trial.
Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors.
Foster CC, Couey MA, Kochanny SE, Khattri A, Acharya RK, Tan YC, Brisson RJ, Leidner RS, Seiwert TY. Foster CC, et al. Among authors: kochanny se. Cancer. 2021 Dec 15;127(24):4565-4573. doi: 10.1002/cncr.33780. Epub 2021 Sep 21. Cancer. 2021. PMID: 34547103 Free article.
Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma.
Nair V, Auger S, Kochanny S, Howard FM, Ginat D, Pasternak-Wise O, Juloori A, Koshy M, Izumchenko E, Agrawal N, Rosenberg A, Vokes EE, Skandari MR, Pearson AT. Nair V, et al. Among authors: kochanny s. JAMA Netw Open. 2022 Apr 1;5(4):e227240. doi: 10.1001/jamanetworkopen.2022.7240. JAMA Netw Open. 2022. PMID: 35416988 Free PMC article.
22 results